Sunday, June 04, 2023

POPULATION GROWTH.

JEWISH KING JESUS IS COMING AT THE RAPTURE FOR US IN THE CLOUDS-DON'T MISS IT FOR THE WORLD.THE BIBLE TAKEN LITERALLY- WHEN THE PLAIN SENSE MAKES GOOD SENSE-SEEK NO OTHER SENSE-LEST YOU END UP IN NONSENSE.GET SAVED NOW- CALL ON JESUS TODAY.THE ONLY SAVIOR OF THE WHOLE EARTH - NO OTHER. 1 COR 15:23-JESUS THE FIRST FRUITS-CHRISTIANS RAPTURED TO JESUS-FIRST FRUITS OF THE SPIRIT-23 But every man in his own order: Christ the firstfruits; afterward they that are Christ’s at his coming.ROMANS 8:23 And not only they, but ourselves also, which have the firstfruits of the Spirit, even we ourselves groan within ourselves, waiting for the adoption, to wit, the redemption of our body.(THE PRE-TRIB RAPTURE)

 THE PATENTS TELL US EVERYTHING HOW THE COVID SCAM STARTED BACK IN 1965 AS A BIOLOGICAL WEAPON TO ATTACK HUMANS.AND DEPOPULATE THE EARTH..

PFIZER FIRST SPIKE PROTENE PATENED IN 1990.
PFIZER SAID VACCINES DON'T WORK ON COVID BECAUSE IT MUTATES IN 1990.


DAVIDS SPEECH ON VIDEO
https://www.youtube.com/watch?v=EONkIQnhVj0

THE GREAT AWAKENING-THE COVID PLANDEMIC

 https://www.infowars.com/posts/watch-the-great-awakening-documentary-exposing-covid-plandemic/


foreign it is a it is a particularly interesting location for me to be sitting today given that over a decade ago I sat in this very chair right here in the European Union Parliament and at that time I warned the world of what was coming during that conversation that was hosted at the time by the green and EFA and a number of the other parties of the European unions various representations we were having a conversation on whether Europe should adopt the United States policy of allowing for the patents on biologically derived materials and at the time I urge this body and I urge people around the world that the weaponization of nature Against Humanity had dire consequences tragically I sit here today with that unfortunate line that I don't like to say which I told you so but the fact of the matter is we're here not for a reprisal on past decisions we're here to actually once again come to the face of the human condition and ask the question who do we want to be what do we want Humanity to look like and rather than seeing this as an exercise in futility which is very easy from time to time when you're in the position I'm in I actually see this not as an exercise in futility I see this as one of the greatest opportunities that faces us because we now have a public conversation which is now front and center in people's minds when this was an esoteric conversation about biological patents nobody cared but when that conversation came home then it became something people can care about so I'm actually quite grateful for this opportunity I thank the members of parliament for hosting this I thank all of the translators who I apologize in advance I will use terminology that is probably very difficult to translate so my apologies I'd also like to acknowledge the fact that many of you are aware of my involvement with this in large part due to the amazing work of my wonderful wife Kim Martin who encouraged me at the very early days of this pandemic to get on front of the camera and talk about all the information that I had been sharing among very small groups around the world and it was in fact her encouragement that put me in a place where many of you have heard what I have to say ironically the world that I came from that used to be very popular my CNBC and Bloomberg presentations which were televised on mainstream media around the world was an audience that I lost I I can confidently say covid diminished my fame but I can also confidently say that I'd rather stand among the people with whom I'm standing today than any of the folks that were part of that previous world so this is a much better place to be my role today is to set the stage for this conversation in a historical context because this did not come in the last three years this did not come in the last five or six years this actually is an ongoing question that probably began here in Europe in the early stages of the mid 1900s but certainly by 1913 1914 this conversation started right here in Central Europe the pandemic that we alleged to have happen in the last few years also did not happen overnight in fact the very specific pandemic using coronavirus began in a very different time and we'll try to advance the slides here with one of these things up there we go most of you don't know that coronavirus as a model of a pathogen was isolated in 1965.

COVID STARTED IN FULL GEAR IN 1945 AFTER THE 1913 - 1914 START.

coronavirus was identified in 1965 as one of the first infectious replicatable viral models that could be used to modify a series of other experiences of the human condition it was isolated Once Upon a Time associated with the common cold but what's particularly interesting about its isolation in 1965 was that it was immediately identified as a pathogen that could be used and modified for a whole host of reasons and you heard me correctly that was 1965 and by the way these slides are public domain you're welcome to look at every single reference every comment that I made is based on published material so do make sure that you look at those references but in 1966 the very first COV coronavirus model was used as a transatlantic biological experiment in human manipulation and you heard the date 1966. I hope you're getting the point of what I'm saying this is not an overnight thing this is actually something that's been long in the making a year before I was born we had the first transatlantic coronavirus data sharing experiment between the United States and the United Kingdom and in 1967 the year I was born we did the first human trials on inoculating people with modified Coronavirus amazing 56 years ago the overnight success of a pathogen that's been 56 years in engineering and I want that to chill with all of you where were we when we actually allowed in violation of biological and chemical weapons treaties where were we as a human civilization when we thought it was an acceptable thing to do to take a pathogen for the United States and infect the world with it where was that conversation and what should have been that conversation in 1967. that conversation wasn't had ironically the common cold was turned into a chimera in the 1970s and in 1975 1976 and 1977 we started figuring out how to modify coronavirus by putting it into different animals pigs and dogs and not surprisingly by the time we got to 1990 we found out that coronavirus as a infectious agent was an industrial problem for two primary Industries the industries of dogs and pigs dog breeders and pigs found that coronavirus created gastrointestinal problems and that became the basis for Pfizer's first Spike protein vaccine Patent filed are you ready for this in 1990 did you hear what I just said 1990 operation warp speed I'm sorry where's the warp and the speed Pfizer 1990 the very first Spike protein vaccine for Coronavirus foreign isn't that fascinating isn't it fascinating that we were we were told that well the spike protein is a new thing we just found out that that's the problem no as a matter of fact we didn't just find out it was not just now now the problem we found that out in 1990 and filed the first patents on vaccines in 1990 for the spike protein of Coronavirus and who would have thought Pfizer clearly the innocent organization that does nothing but promote human health clearly Pfizer the organization that has not bought the votes in this chamber and at every chamber of every government around the world not that Pfizer certainly they wouldn't have had anything to do with this but oh yes they did and in 1990 they found out that there was a problem with vaccines they didn't work you know why they didn't work it turns out the coronavirus is a very malleable model it transforms and it changes and it mutates over time as a matter of fact every publication on vaccines for Coronavirus from 1990 until 2018 every single publication concluded that coronavirus escapes the vaccine impulse because it modifies and mutates too quickly for vaccines to be effective and since 1990 to 2018 that is the published science ladies and gentlemen that's following the science following the science is their own indictment of their own programs that said it doesn't work and there are thousands of Publications to that effect not a few hundred and not paid for by pharmaceutical companies these are Publications that are independent scientific research that shows unequivocally including efforts of the Chimera modifications made by Ralph Barrick in the University of North Carolina Chapel Hill all of them show vaccines do not work on Coronavirus that's the science and that science has never been disputed but then we had an interesting development in 2002 and this date is most important because in 2002 the University of North Carolina Chapel Hill patented and I quote an infectious replication defective clone of Coronavirus listen to those words infectious replication defective what does that phrase actually mean for those of you not familiar with language

INFECTIOUS REPLICATION DEFECTIVE MEANS.

let me unpack it for you infectious replication defective means a weapon it means something meant to Target an individual but not have collateral damage to other individuals that's what infectious replication defective means and that patent was filed in 2002 on work funded by niaid's Anthony fauci from 1999 to 2002 and that work patented at the University of North Carolina Chapel Hill mysteriously preceded SARS 1.0 by a year Dave are you suggesting that SARS 1.0 wasn't from a wet Market in Wuhan are you suggesting it might have come from a laboratory in the University of North Carolina Chapel Hill no I'm not suggesting it I'm telling you that's the facts we engineered SARS SARS is not a naturally occurring phenomenon the naturally occurring phenomenon is called the common cold it's called influenza-like illness it's called gastroenteritis that's the naturally occurring Coronavirus SARS is the research developed by humans weaponizing a life system model to actually attack human beings and they patented it in 2002.[Applause] and in 2003 giant surprise the CDC filed the patent on coronavirus isolated from humans in violation once again of biological and chemical weapons treaties and laws that we have in the United States and I'm very very precise on this the United States likes to talk about its rights and everything else and the rule of law and all the nonsense that we like to talk about but we don't ratify treaties about I don't know defending humans we conspicuously avoid that we actually have a great track record of advocating for human rights and then denying them when it comes to actually being part of the International Community which is a slightly problematic thing but let's get something very clear when the CDC in April of 2003 filed the patent on SARS coronavirus isolated from humans what did they do they downloaded a sequence from China and filed a patent on it in the United States any of you familiar with biological and chemical weapons treaties knows that's a violation that's a crime that's not an innocent oops that's a crime and the United States patent office went as far as to reject that patent application on two occasions until the CDC decided to bribe the patent office to override the patent examiner to ultimately issue the patent in 2007 on SARS coronavirus but let's not let that get away from us because it turns out that the rtpcr which was the test that we allegedly were going to use to identify the risks associated with Coronavirus was actually identified as a bioterrorism threat by me in the European union-sponsored events in 2002 and 2003.20 years ago that happened here in Brussels and across Europe in 2005 this particular pathogen was specifically labeled as a bioterrorism and bioweapon platform technology described as such that's not my terminology that I'm applying to it it was actually described as a bioweapons platform technology in 2005.and from 2005 onwards it was actually a bio Warfare enabling agent its official classification from 2005 forward I don't know if that sounds like public health to you does it biological warfare enabling technology that feels like not Public Health that feels like not medicine that feels like a weapon designed to take out Humanity that's what it feels like and it feels like that because that's exactly what is we have been lured into believing that Eco Health Alliance and DARPA and all of these organizations are what we should be pointing to but we've been specifically requested to ignore the facts that over 10 billion dollars have been funneled through Black Operations through the check of Anthony fauci and a side-by-side Ledger where niaid has a balance sheet and next to it is a biodefense balance sheet equivalent dollar for dollar matching that no one in the media talks about and it's been going on since 2005.our gain of function moratorium the moratorium That was supposed to freeze any efforts to do gain a function research conveniently in the fall of 2014 the University of North Carolina Chapel Hill received a letter from niid saying that while the gain of function moratorium on coronavirus in Vivo should be suspended because their grants had already been funded they received an exemption did you hear what I just said a biological weapons lab facility at the University of North Carolina Chapel Hill received an exemption from the gain of function moratorium so that by 2016 we could publish the the journal article that said SARS coronavirus is poised for human emergence in 2016

WAS THE CORONAVIRUS POISED FOR HUMAN EMERGENCE.

and what you might ask Dave was the coronavirus poised for human emergence it was w i v one Wuhan Institute of virology virus 1.poised for human emergence in 2016. at the proceedings of the National Academy of Sciences such that by the time we get to 2017 and 2018 the following phrase entered into common parlance among the community there is going to be an accidental or intentional release of a respiratory pathogen the operative word obviously in that phrase the word release does that sound like leak does that sound like a bat and a Pangolin went into a bar in the Wuhan market and hung out and had sex and and lo and behold we got SARS cov2 no accidental or intentional release of a respiratory pathogen was the terminology used and four times in April of 2019.seven months before the allegation of patient number one four patent applications of moderna were modified to include the term accidental or intentional release of a respiratory pathogen as the justification for making a vaccine for a thing that did not exist keep going if you have not done so please make sure that you make reference in every investigation to the premeditation nature of this because it was in September of 2019 that the world was informed that we were going to have an accident or intentional release of a respiratory pathogen so that by September 2020 there would be a worldwide acceptance of a universal vaccine template that's their words right in front of you on the screen the intent was to get the world to accept a universal vaccine template and the intent was to use coronavirus to get there and the last slide this is an advancing so if I could have somebody to do it let's let's read this because we have to read this into the record everywhere I go until an infectious disease crisis is very real present and at the emergency threshold that is often largely ignored to sustain the funding base beyond the crisis he said we need to increase the public understanding for the need for medical countermeasures such as a pan influenza or pan coronavirus vaccine a key driver is the media and the economics will follow the hype we need to use that hype to our advantage to get to the real issues investors will respond if they see profit at the end of the process.

ANTHONY FAUCCI, BILL GATES AND ALL LAME BRAIN PROPAGANDA MEDIA INVOLVED WITH COVID ARE DOMESTIC TERRORISTS USING CHEMICAL AND BIOLOGICAL WEAPONS ON EARTHS POPULATION FOR OR MONEY AND DEPOPULISING THE WORLD.

sounds like Public Health sounds like the best of humanity no ladies and gentlemen this was premeditated domestic terrorism stated at the proceedings of the National Academy of Sciences in 2015 published in front of them this is an this is an act of biological and chemical warfare perpetrated on the human race and it wasadmitted to in writing that this was a financial Heist and a financial fraud investors will follow if they see profit at the end of the process let me conclude by making five very brief recommendations the last slide foreign nature was hijacked this whole story started in 1965 when we decided to hijack a natural model and decide to start manipulating it science was hijacked when the only questions that could be asked were questions authorized under the patent protection of the CDC the FDA the NIH and their equivalent organizations around the world we didn't have independent science we had hijacked science and unfortunately it was no moral oversight in violation of all of the codes that we stand for there was no independent financially disinterested independent review board ever impaneled around coronavirus not once not once not since 1965.we do not have a single independent IRB ever impaneled around coronavirus so morality was suspended for medical countermeasures and ultimately Humanity was lost because we decided to allow it to happen our job today is to say no more gain of function research period no more weaponization of nature period foreign most importantly no more corporate patronage of science for their own self-interest unless they assume 100 product liability for every injury and every death that they maintain thank you very much foreign DAVID MARTIN OF THE EUROPEAN UNION GOVERNMENT.

THANK YOU DAVE MARTIN FOR REVEALING THIS MONEY, DEPOPULATION, DOMESTIC TERRORIST KILLER VACCINE SCAM THAT STARTED BACK IN 1965.THE PATENTS DO TELL THE STORY OF THESE SLITHERING DEMONIC SNAKES FACCI, BILL GATES AND DEMOLIBNUT MEDIA PROPAGANDISTS PAID WHORES.

PFIZER PATENTS
https://patents.justia.com/search?q=PFIZER+PATENTS
COVID PATENTS
https://patents.justia.com/search?q=COVID+PATENTS
COVID VACCINE PATENTS
https://patents.justia.com/search?q=COVID+VACCINE+PATENTS


Patents by Inventor Anthony S. Fauci

Anthony S. Fauci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

    Use of antagonists of the interaction between HIV GP120 and ?4?7 integrin
    Patent number: 9896509
    Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: February 20, 2018
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci

    USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND A4B7 INTEGRIN
    Publication number: 20160333097
    Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.
    Type: Application
    Filed: August 3, 2016
    Publication date: November 17, 2016
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv
    Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci
    Use of antagonists of the interaction between HIV GP120 and ?4?7 integrin
    Patent number: 9441041
    Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: September 13, 2016
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci

    USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND A4B7 INTEGRIN
    Publication number: 20160075786
    Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.
    Type: Application
    Filed: September 21, 2015
    Publication date: March 17, 2016
    Applicant: The United States of America, as Represented by the Secretary, Department of Health and Human Serv
    Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci

    IMMUNOCONJUGATES COMPRISING CD4 AND IMMUNOGLOBIN MOLECULES FOR THE TREATMENT OF HIV INFECTION
    Publication number: 20090285815
    Abstract: Nucleic acids encoding recombinant CD4-fusion proteins are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C terminus of the heavy chain of an IgA antibody or a tailpiece from a C terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins.
    Type: Application
    Filed: March 21, 2008
    Publication date: November 19, 2009
    Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci

    Fusion protein including of CD4
    Patent number: 7368114
    Abstract: Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion or the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody ara tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4 fusion proteins.
    Type: Grant
    Filed: October 24, 2002
    Date of Patent: May 6, 2008
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci

    HIV related peptides
    Patent number: 6911527
    Abstract: This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1 infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling progression to AIDS.
    Type: Grant
    Filed: January 7, 2000
    Date of Patent: June 28, 2005
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Giuseppe Scala, Xueni Chen, Oren J. Cohen, Anthony S. Fauci
    Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
    Publication number: 20040265306
    Abstract: Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody or a tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins.
    Type: Application
    Filed: July 27, 2004
    Publication date: December 30, 2004
    Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci

    Immunologic enhancement with intermittent interleukin-2 therapy
    Publication number: 20030180254
    Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.
    Type: Application
    Filed: January 23, 2003
    Publication date: September 25, 2003
    Applicant: The Govt. of the USA as represented by the Secretary of the Dept. of Health & Human Services
    Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci

    Immunologic enhancement with intermittent interleukin-2 therapy
    Patent number: 6548055
    Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: April 15, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci

    Immunologic enhancement with intermittent interleukin-2 therapy
    Patent number: 6190656
    Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.
    Type: Grant
    Filed: September 2, 1997
    Date of Patent: February 20, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci

    Immunologic enhancement with intermittent interleukin-2 therapy
    Patent number: 5696079
    Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: December 9, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci

ALLTIME